Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts

Q4 2024 revenue of $1.5 million in pharma services; full year revenue of$1.9 millionGraftAssure RUO assay launched July 2024Signed strategic partner and investor, Bio-Rad LaboratoriesFully funded clinical kitted product development with $50+ million in equity raisesAdvanced science in transplant; achieved Medicare claims expansion IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunc ...